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Accelerating regional atrophy rates
in the progression from normal aging
to Alzheimer’s disease
Abstract We investigated progres-
sion of atrophy in vivo, in Alzheimer’s
disease (AD), and mild cognitive
impairment (MCI). We included 64
patients with AD, 44 with MCI and 34
controls with serial MRI examinations
(interval 1.8±0.7 years). A nonlinear
registration algorithm (fluid) was used
to calculate atrophy rates in six
regions: frontal, medial temporal,
temporal (extramedial), parietal, oc-
cipital lobes and insular cortex. In
MCI, the highest atrophy rate was
observed in the medial temporal lobe,
comparable with AD. AD patients
showed even higher atrophy rates in
the extramedial temporal lobe. Addi-
tionally, atrophy rates in frontal,
parietal and occipital lobes were
increased. Cox proportional hazard
models showed that all regional atro-
phy rates predicted conversion to AD.
Hazard ratios varied between 2.6
(95% confidence interval (CI) = 1.1–
6.2) for occipital atrophy and 15.8
(95% CI=3.5–71.8) for medial tem-
poral lobe atrophy. In conclusion,
atrophy spreads through the brain with
development of AD. MCI is marked
by temporal lobe atrophy. In AD,
atrophy rate in the extramedial tem-
poral lobe was even higher. Moreover,
atrophy rates also accelerated in
parietal, frontal, insular and occipital
lobes. Finally, in nondemented el-
derly, medial temporal lobe atrophy
was most predictive of progression to
AD, demonstrating the involvement of
this region in the development of AD.
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Alzheimer’s disease (AD) is a neurodegenerative disease,
characterised by progressive cognitive decline and cerebral
atrophy. Patients with mild cognitive impairment (MCI)
have measurable cognitive deficits, but do not fulfil criteria
for dementia [1]. Subjects with MCI are at an increased risk
of developing AD with about 10–15% progressing to AD
per year: in these subjects MCI may be considered to be a
transitional phase for AD [2].
Neuropathological studies suggest that Alzheimer’s
pathology spreads throughout the brain in a relatively
predictable fashion and starts well before clinical onset of
disease [3]. However, by definition, neuropathological
studies are post hoc and cross-sectional in design and
clearly cannot track disease progression in the individual.
Magnetic resonance imaging (MRI) of the brain shows
atrophy in vivo, particularly involving the medial temporal
lobe, early in the disease [4]. In contrast to neuropatholo-
gical studies, serial MRI is feasible and enables in vivo
study of progression of the disease throughout the brain [4,
5]. Serial measures allow each subject to act as their own
control and thereby avoid the wide variability in brain
morphology between subjects. In particular hippocampal
atrophy rates have shown to be sensitive markers of AD,
and predict progression of cognitive decline more accu-
rately than cross-sectional volumes [6–8]. However,
whole-brain atrophy rates also distinguish patients with
AD and MCI from controls, suggesting the additional early
involvement of brain regions other than the hippocampus
[5, 9, 10].
We studied progression of atrophy in six lobar brain
regions in AD, MCI and control subjects. We hypothe-
sised that atrophy rates of MCI patients would be highest
in the medial temporal lobes, consistent both with this
region’s early pathological involvement and its associa-
tion with memory function—often the presenting symp-
tom [3]. With advancing disease, we expected atrophy
rates of AD patients to increase in other brain regions as
well. This study aimed to compare the pattern of regional
atrophy rates in AD, MCI and controls. In addition, we
investigated associations between regional atrophy rates
and clinical progression to AD in initially nondemented
patients.
Material and methods
Patients
Baseline clinical assessment
We included 64 patients with probable AD, 44 patients
with MCI and 34 controls. All patients underwent a
standardised clinical assessment including medical histo-
ry, physical and neurological examination and psycho-
metric evaluation. All subjects had serial volumetric MR
imaging. The mini-mental state examination (MMSE) was
used as a measure of general cognitive function [11].
Diagnoses were established during a multidisciplinary
consensus meeting according to the Petersen criteria for
MCI[12]and the NINCDS-ADRDA (National Institute of
Neurological and Communicative Diseases and Stroke/
Alzheimer’s Disease and Related Disorders Association)
criteria for probable AD [13]. The control group consisted
of 26 patients who presented at our memory clinic with
subjective complaints, but who had normal clinical
investigations and did not have significant cognitive
deficits (i.e. MCI criteria were not fulfilled). Additionally,
we included eight volunteers without cognitive com-
plaints, who were willing to undergo the same diagnostic
procedure as patients attending our memory clinic. The
study was approved by the institutional ethical review
board. All participants (or caregivers) gave written
informed consent.
Clinical assessment at follow-up
Diagnostic classification of nondemented participants
(MCI and controls) was re-evaluated at follow-up. The
clinical diagnosis of dementia was determined according to
published consensus criteria [12–16]. Within the MCI
group, 16 patients had remained stable, 23 progressed to
AD, two to frontal-temporal lobar degeneration (FTLD)
[14], two to vascular dementia (VaD) [15] and one to
dementia with Lewy bodies (DLB) [16]. Within the group
of controls, three progressed to MCI, three to AD and one
to FTLD, whilst 27 controls remained stable.
MRI
MR imaging was performed on a 1.0-T Siemens
Magnetom Impact Expert (Siemens AG, Erlangen,
Germany) and included coronal T1-weighted 3D
MPRAGE volumes (magnetization prepared rapid acqui-
sition gradient echo; single slab, 168 slices; matrix size
256×256; FOV 250 mm; voxel size 1×1×1.5 mm; TR=
15 ms; TE=7 ms; TI=300 ms; flip angle 15°). For
inclusion subjects had to have had two MR examinations
withoutartefacts,performedonthesameMRsystemusing
the same imaging protocol. Images were reviewed by a
neuroradiologist to exclude non-neurodegenerative pa-
thology that could explain the cognitive impairment.
Patients with baseline MR examinations that fulfilled
radiological criteria of the NINDS-AIREN for vascular
dementia were excluded [15].
Regional atrophy rates between two time-points were
measured from the 3D-T1 MPRAGE images using fluid
registration, a nonlinear matching algorithm [17, 18].
This algorithm requires the baseline and repeat image to
2827be aligned, and intensity to be normalised within and
between volumes. We used the following preprocessing
steps:
. All images were bias-corrected using N3 software
(http://www.bic.mni.mcgill.ca/software/N3/)[ 19].
. Images from the two time-points of each subject were
linearly coregistered to a halfway position, using the
skull-based scaling constraint as implemented in the
SIENA software (structural brain change analysis, for
estimating brain atrophy), part of the FSL suite (http://
www.fmrib.ox.ac.uk/fsl/)[ 20].
. Residual bias field differences between the two time-
points were then removed using differential bias
collection (DBC) as described by Lewis and Fox [21].
. A brain mask was extracted from the resulting images
using BET (brain extraction tool) combined with
registration of a standard mask using FLIRT (FMRIB’s
linear image registration tool) [22].
. The brain mask was expanded to induce a Gaussian
signal drop-off in space around the brain tissue.
After preprocessing, nonlinear registration between the
registered baseline and repeat images was performed, using
a nonlinear voxel-compression technique (fluid) [17]. This
technique uses a viscous fluid model to compute the
transformation required to bring one image in register with
the other, using cross correlation as a similarity function.
The data analysis for the whole data set required around
1,200 computing hours, and was performed in the GRID
infrastructure provided by the Virtual Laboratory for e-
Sciences project (www.vl-e.nl). By using trivially parallel
computing the entire dataset could be processed in a single
weekend. Visual inspection of the results confirmed that in
all cases the registration had succeeded (i.e. all image pairs
were well matched and the algorithm had succeeded in
deforming the latter MR examinations compared with the
baseline—effectively removing the effects of atrophy).
From the transformation field created by each registration,
we generated a map of Jacobian determinants; these are a
measure of the volume change (compression or expansion)
at each voxel required to match the examinations precisely.
Examples of these voxel-compression (Jacobian) maps are
shown in Fig. 1.
We then defined six lobar regions as follows: first brain
tissue was separated from nonbrain using FAST (FMRIB’s
automated segmentation tool) [22]; secondly, the AAL
mask (automated anatomical labeling)[23] was coregis-
tered to the individual data. We used the subdivisions of the
AAL mask of six predefined lobar regions: frontal, medial
temporal (hippocampus, parahippocampal gyrus, and
amygdala), temporal (excluding medial temporal), parietal,
occipital lobes and insular cortex. For every patient, we
averaged the relative volume change over all voxels in each
region, and divided by the follow-up time in years between
MR examinations to obtain annualized regional atrophy
rates.
Statistical analysis
Statistical analysis was performed with SPSS 12.0 (2003,
Chicago, Illinois). Follow-up time was defined as the
interval in years between baseline and repeat MR
examinations. Diagnostic groups were compared with
chi-squared tests for sex. For continuous variables we
used analysis of variance (ANOVA), with age and sex as
covariates. Post hoc comparisons were performed using
Bonferroni tests. Differences in regional atrophy rates
between groups were assessed using ANOVA for repeated
measures with region as within-subjects factor, diagnosis as
between-subjects factor, and age and sex as covariates. In
addition, within the group of initially nondemented partici-
pants we assessed the predictive value of regional atrophy
rates, by using Cox proportional hazards models, which
account for variability in length of follow-up. Results are
presented as hazard ratios (HRs) with 95% confidence
interval (CI). The main outcome was progression to
dementia, while the secondary outcome was progression to
AD,whichexcludessixcaseswhodevelopedadifferenttype
of dementia. Regional atrophy rates (dichotomized into high
and low rates of atrophy, based on the median) were used as
independent variables in separate models, adjusted for age
and sex. Time-to-event curves were constructed with the
Kaplan–Meier method. Statistical significance was set at
p<0.05.
Results
Demographics and clinical data are presented by patient
group in Table 1. No between-group difference in sex or
follow-up time was found. MCI patients were older than
AD patients and controls. Frontal, medial temporal,
temporal (excluding medial temporal), parietal, occipital
and insular atrophy rates are given in Table 1. ANOVA for
repeated measures with region as within-subjects factor,
group as between-subjects factor, and age and sex as
covariates showed main effects of diagnostic group (p<
0.001) and region (p<0.001), and an interaction between
diagnosis andregion(p<0.001),indicating differentpatterns
of regional atrophy rates according to diagnostic group.
Figure 2 shows that for MCI patients, the highest annualized
atrophy rates were observed not only in the medial temporal
lobe, but also in the remaining (extramedial) part of the
temporal lobe. With progression of the disease, the atrophy
appears to spread more widely through the brain, with
patients with clinically established AD showing higher
atrophyratesintemporal,frontal,parietalandoccipitallobes.
The atrophy rate in the medial temporal lobe appears to
already have reached its maximum at a stage prior to clinical
diagnosis,asthisratedidnotincreasefurtherinpatientswith
AD when compared with MCI patients.
Subsequently, we assessed the predictive value of
regional atrophy rates for the prediction of dementia in
2828Fig. 1 Baseline MR examina-
tion (left), repeat MR examina-
tion (middle) and colour overlay
overlaid on the baseline exami-
nation (right) of four individual
patients: a 50-year-old control
subject, who presented at the
memory clinic with subjective
memory complaints (A); a 72-
year-old MCI patient who re-
mained stable during follow-up
(B); a 69-year-old MCI patient
who progressed to AD during
follow-up (C); a 64-year-old,
moderately demented AD pa-
tient (D). Baseline and repeat
examinations were affine-regis-
tered. The result of the nonlinear
registration is presented as a
colour overlay applied to the
baseline examination (repre-
senting the local Jacobian of the
calculated deformation field), in
order to highlight regions of
structural expansion and con-
traction. Green and blue
represent moderate to severe
contraction (atrophy), yellow
and red moderate to severe
expansion. The overlay image
was masked with a dilated mask
to also show expansion of pe-
ripheral CSF spaces
2829initially nondemented patients (controls and MCI, n=78).
Thirty-two patients progressed to dementia, while 46
patients remained stable. No differences were found
between patients progressing to dementia and patients
who remained stable during follow-up, for sex (female/
male 17/15 versus 20/26; p=0.57), age (mean±sd 71±6
versus 68±9; p=0.14) or duration of follow-up (1.8±
0.7 years versus 1.9±0.8 years; p=0.53). There was a
difference in baseline MMSE score between progressing
and stable patients (26±3 versus 28±2; p<0.001). Age-
and sex-adjusted Cox proportional hazard models showed
that atrophy rates in all regions were associated with an
increased risk of progression to dementia (Table 2). Risk
estimates varied between 2.0 (95% confidence interval,
CI=0.9–4.4) for occipital lobe atrophy rate and 6.4 (95%
CI=2.4–17.3) for medial temporal lobe atrophy rate. As an
example, Fig. 3 shows the Kaplan–Meier survival curve for
the medial temporal lobe. When the analysis was repeated
and restricted to progression to AD (excluding six patients
who developed other types of dementia) the risk estimates
were even higher. Atrophy rates in the medial temporal
lobe remained the best predictor in the model, HR 15.8
(95% CI=3.5–71.8). In addition, the temporal lobe
(nonmedial) and parietal lobe were good predictors of
progression to AD. When we repeated the analysis with
additional adjustment for baseline MMSE, results re-
mained largely unaltered (data not shown).
Discussion
The main finding of our study is that the pattern of regional
atrophy rates differs in patients with MCI and AD when
compared with controls. These data suggest how atrophy
rates accelerate through the brain with the progression of
cognitive decline. In MCI, the temporal lobe shows the
greatestatrophyrate,butatrophyalreadyextendsbeyondthe
medial temporal lobe, with atrophy rates in the extramedial
partofthe temporallobeevenatthisstage appearing equally
high. Atrophy rates in the medial temporal lobe were no
higher in the AD patients than in the MCI patients, implying
that rate of neurodegeneration in this region is already
maximalpriortoclinicaldiagnosis.TheprogressiontoADis
characterised by increasing atrophy rates in the rest of the
temporal lobe, and atrophy also accelerating in parietal,
frontalandoccipitallobes.Nonetheless,medialtemporallobe
atrophy was most predictive of progression to dementia in
initially nondemented patients. Mainly subjects with a higher
than median atrophy rate were associated with a 15-fold
higher risk of developing AD, when compared with those
with a lower than median atrophy rate during follow-up.
Previous studies report increased cerebral atrophy rates
and ventricular enlargement in AD versus controls [9, 24].
Most cross-sectional MRI studies have focussed on
atrophy of medial temporal lobe structures, commonly
Table 1 Demographic and clinical variables by diagnostic group
Controls MCI AD Overall p value
Number of participants 34 44 64
Outcome (numbers)
Stable 30 16 –
Remaining stable 3 AD 23 AD
Converting 1 other 5 other
Sex (female/male) 16/18 21/23 38/26 p=0.37
Age (years) 67 (9)
** 71 (6) 67 (8)
** p<0.001
MMSE baseline 28 (2) 26 (3)
* 22 (5)
***,**** p<0.001
MR examination interval (years) 1.9 (0.9) 1.9 (0.7) 1.7 (0.6) p=0.39
Regional atrophy rates (%/year)
Frontal −0.6 (0.7) −0.9 (0.7) −1.3 (0.8)
*** p<0.001
Medial temporal −0.6 (0.7) −1.5 (0.7)
*** −1.5 (0.7)
*** p<0.001
Temporal (extramedial) −0.6 (0.5) −1.4 (0.8)
*** −2.2 (1.0)
***,**** p<0.001
Parietal −0.5 (0.5) −0.9 (0.7)
* −1.7 (0.9)
***,**** p<0.001
Occipital −0.4 (0.4) −0.8 (0.6)
*** −1.4 (1.0)
***,**** p<0.001
Insular cortex −0.3 (0.7) −0.7 (0.6) −0.8 (0.8)
*** p<0.001
Data are displayed as mean with standard deviation (sd) in parenthesis. Differences between groups were assessed using ANOVA (age and
sex as covariates where appropriate) with post hoc Bonferroni tests. Group difference for sex was calculated with the Pearson chi-square
test. Medial temporal lobe is defined as hippocampus, parahippocampal gyrus, and amygdala. Temporal lobe is defined as temporal lobe
excluding medial temporal lobe
MCI mild cognitive impairment, AD Alzheimer’s disease, MMSE mini-mental state examination
*p<0.05 compared with controls;
**p<0.05 compared with MCI;
***p<0.001 compared with controls;
****p<0.001 compared with MCI
2830using volumetric measures. These studies have shown that
hippocampal volumes at the time of clinical diagnosis are
on average 18% lower when compared with controls [6,
25]. Whole-brain volumes are decreased in AD also, and
tend to be around 5% lower—this volume loss cannot be
accounted for by medial temporal lobe damage and implies
widespread atrophy beyond this region [10]. Voxel-based
morphometry studies have shown using cross-sectional
comparisons that in addition to atrophy of medial temporal
lobe structures, temporal-parietal atrophy is prominent in
AD [26–28]. In MCI patients progressing to AD versus
stable MCI patients atrophy of the temporal lobe, and to a
Table 2 Risk of progression to dementia associated with regional atrophy measures
Median atrophy rate Outcome = dementia
(n=78)
Outcome = AD
(n=72)
%/year (IQ range) HR (CI) HR (CI)
Frontal lobe −0.8 (−1.2 to −0.4) 2.2 (1.0–4.9) 2.8 (1.1–6.8)
Medial temporal lobe −0.9 (−1.5 to −0.3) 6.4 (2.4–17.3) 15.8 (3.5–71.8)
Temporal lobe −0.9 (−1.4 to −0.4) 3.9 (1.7–9.2) 6.3 (2.2–18.7)
Parietal lobe −0.6 (−1.0 to −0.2) 3.4 (1.4–8.3) 5.1 (1.8–14.8)
Occipital lobe −0.5 (−0.9 to −0.2) 2.0 (0.9–4.4) 2.6 (1.1–6.2)
Insular cortex −0.4 (−0.9 to 0) 2.5 (1.1–5.9) 2.9 (1.2–7.3)
Median atrophy rate is displayed as median (interquartile (IQ) range). Other data are presented as age- and sex-adjusted hazard ratios (HR)
and 95% confidence interval (CI). In the third column, six patients who progressed to another type of dementia were excluded
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Fig. 2 Regional atrophy rate in six predefined lobar regions are
presented by diagnostic group: frontal, medial temporal (hippocam-
pus, amygdala, parahippocampal gyrus), temporal (extramedial),
parietal, occipital and insular lobe. In controls, atrophy rates are
around 0.5%/year for each region. In MCI patients, atrophy rates
start to accelerate mainly in the medial temporal, and remaining
temporal lobe (extramedial), and to a lesser extent in the other
regions. AD is characterised by a further increase in atrophy rate in
the remainder of the temporal lobe, parietal, frontal, occipital and
insular lobe. Medial temporal lobe atrophy rates appear to be at a
maximum, in the preclinical stage, since the rate is comparable to
that of MCI patients. Δ = controls (light grey line); □ = MCI (dark
grey line); ○ =A D( black line)
Numbers at risk (n=78):
Low atrophy rate (n=39) 25 7
High atrophy rate (n=39) 19 5 
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Fig. 3 Kaplan–Meier curve of time-to-conversion in initially
nondemented patients (n=78) dependent on medial temporal lobe
atrophy rate. Nondemented patients were dichotomised into either
the high or the low category, based on median medial temporal lobe
atrophy rate (−0.9%/year). Numbers at risk are displayed below
graph. Participants reaching end of follow-up period without
progression to dementia were censored. Low atrophy rate (dashed
grey line); high atrophy rate of the medial temporal lobe (solid black
line); + = censored
2831lesser extent of the parietal and frontal lobe was shown
[29–31]. Longitudinal measures of atrophy, which allow
changes within the individual to be assessed, have been
shown to be more sensitive at detecting group differences
than cross-sectional volumes, in part because they are less
susceptible to intersubject variability [4, 32, 33]. A number
of studies described the pattern of longitudinal atrophy in
relatively small groups of sporadic and familial AD
patients. They found increased atrophy in the medial
temporal lobe over time, but also more widespread
throughout the brain, in the parietal and frontal lobe [17,
34]. Longitudinal studies report that hippocampal atrophy
rates increase in MCI [6–8]. We extend these findings, by
providing rates of atrophy in six brain regions. Our study
confirms that the medial temporal lobe is affected at an early
stage of the disease. Additionally, we found the mean
atrophy rate in the remainder of the temporal lobe to be
increasedatanearlystageaswell,beforeaclinicaldiagnosis
could be made with certainty. Regional atrophy rates in the
remainder of the cortex further accelerated in AD.
Among the limitations of our study is the fact that the
control group included individuals with subjective com-
plaints. At baseline, we found no differences between
healthy volunteers and patients with subjective complaints,
and we therefore pooled these subjects in one control
group. However, patients presenting at a memory clinic
with subjective complaints are known to have a higher risk
of developing AD [35, 36]. In fact, three patients converted
to AD and one to FTLD. One could argue that these
patients should have been excluded, as they did not remain
control-like throughout the study. However, we feel that,
since they fulfilled initial inclusion criteria, excluding these
patients would bias the results. Looking back at the
regional atrophy rates, the patients who progressed to AD
showed high atrophy rates, congruent with their clinical
progression. Regional (including frontal) atrophy rates of
the patient who progressed to FTLD were not remarkable.
A second limitation was that no postmortem verification of
diagnosis, which is considered the gold standard for
diagnosing AD, was available. We therefore cannot
exclude the possibility that some of our patients were
misdiagnosed. Even though our MCI patients fulfilled the
Petersen criteria, generally regarded as predictive of AD,
five patients progressed to another type of dementia. When
we visually inspected the individual data, the FTLD
progressors showed relatively high frontal atrophy rates,
while the pattern was more generalized for the two patients
with VaD and the patient who progressed to DLB.
Remarkably, none of these five patients showed predomi-
nant medial temporal lobe atrophy, as was generally
observed in MCI patients progressing to AD.
Among the strengths of our study was the relatively large
sample, in which we studied regional atrophy rates, using a
robust method. We used fluid registration, a nonlinear
registration algorithm to match two MR examinations of
each individual. This fully automated voxel-compression
technique has the advantage that changes at a lobar level can
be assessed without time-consuming manual measurement
of regional volumes. Furthermore, the nonlinear registration
matches examinations with shape change as well as volume
loss. This means that the structural readjustments, that are an
inevitable consequence of neurodegeneration, do not con-
found assessment of the distribution of loss.
The results of our study are in agreement with what has
been published about the progression of atrophy through
the brain in neuropathological studies regarding AD [3,
37–40]. Neuropathological studies report that AD pathol-
ogy spreads through the brain in a relatively predictable
fashion [3]. For neurofibrillary tangles the progression can
be separated into six stages: stages I and II show alterations
in the transentorhinal regions, stages III and IVare known
as the limbic stage, while stage V and VI are marked by
widespread isocortical involvement. The accumulation of
amyloid deposits can be divided into three stages: stage A
shows initial deposits in the basal portions of the isocortex,
stage B shows amyloid in virtually all isocortical associ-
ation areas, but the hippocampal formation is only mildly
involved, while in stage C end-stage deposits can be
observed throughout the isocortex. This study demonstra-
ted that the pattern of atrophy, observed in vivo using serial
MRI, more closely resembles the pattern of accumulating
neurofibrillary tangles. Furthermore, the early involvement
of the medial temporal lobe, as observed in neuropatho-
logical studies, has shown to be of clinical importance in
the detection of incipient AD in this study.
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